Profile of Dr Rachel Moore
I joined AstraZeneca in 2018 following the completion of my PhD at the University of Sheffield, where I investigated how endocytosis regulates the JAK/STAT signalling pathway. Since joining AZ I have worked as a Senior Scientist in the global HTS centre, optimising and prosecuting screens across multiple targets and therapeutic areas, using an array of assay technologies. I am particularly interested in developing new methodologies to identify undesirable hits from HTS outputs, and therefore aid project teams in prioritising quality chemical equity.
